Kalbitor from Dyax Corporation and Defiante Farmaceutica S.A. is withdrawn from its application to the EMA for the treatment of...
The FDA has approved an expansion of the indication for Kalbitor (ecallantide), from Dyax, for the treatment of Acute Hereditary...
Shire plc and Dyax Corporation announced that Shire will acquire Dyax for approximately $5.9 billion. Dyax is a Massachusetts-based biotechnology...